Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease

References

• Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med. 1995;333(24):1618–24. PMID:7477199. doi:10.1056/NEJM199512143332408.
   PubMed Web of Science ®Google Scholar
• Miyashita N, Matsushima T, Oka M. Japanese respiratory society. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med. 2006;45(7):419–28. PMID: 16679695. doi:10.2169/internalmedicine.45.1691.
   PubMed Web of Science ®Google Scholar
• Sakiyama H, Joh A, Umemoto T, Shimizu H, Oishi K. Childhood vaccination rates in Japan based on national survey. J Ambulatory Gen Pediatr. 2017;20(3):271–82. (in Japanese).
   Google Scholar
• Ubukata K, Takata M, Morozumi M, Chiba N, Wajima T, Hanada S, Shouji M, Sakuma M, Iwata S. Effects of pneumococcal conjugate vaccine on genotypic penicillin resistance and serotype changes, Japan, 2010–2017. Emerg Infect Dis. 2018;24(11):2010–20. PMID:30334707. doi:10.3201/eid2411.180326.
   PubMed Web of Science ®Google Scholar
• Rokney A, Ben-Shimol S, Korenman Z, Porat N, Gorodnitzky Z, Givon-Lavi N, Ron M, Agmon V, Dagan R, Valinsky L. Emergence of Streptococcus pneumoniae serotype 12F after sequential introduction of 7- and 13-valent vaccines, Israel. Emerg Infect Dis. 2018;24(3):453–61. PMID: 29460732. doi:10.3201/eid2403.170769.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, Andrews NJ, Miller E, Ramsay ME. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–51. PMID: 29395999. doi:10.1016/S1473-3099(18)30052-5.
   PubMed Web of Science ®Google Scholar
• Shimbashi R, Chang B, Tanabe Y, Takeda H, Watanabe H, Kubota T, Kasahara K, Oshima K, Nishi J, Maruyama T, et al. Epidemiological and clinical features of invasive pneumococcal disease caused by serotype 12F in adults, Japan. PLoS One. 2019;14(2):e0212418. PMID: 30789928. doi:10.1371/journal.pone.0212418.
   PubMed Web of Science ®Google Scholar
• Gutiérrez Rodríguez MA, Ordobas Gavin MA, Garcia-Comas L, Sanz Moreno JC, Cordoba Deorador E, Lasheras Carbajo MD, Taveira Jimenez JA, Martin Martinez F, Iniesta Fornies D, Arce Arnaez A. Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the region of Madrid, Spain, 2008–2011. Euro Surveill. 2014;19(40):20922. PMID: 25323079. doi:10.2807/1560-7917.es2014.19.40.20922.
   PubMedGoogle Scholar
• Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30(48):6802–08. doi:10.1016/j.vaccine.2012.09.019. PMID: 23000122.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348(18):1747–55. PMID: 12724480. doi:10.1056/NEJMoa022678.
   PubMed Web of Science ®Google Scholar
• Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis. 2003;3(2):71–78. PMID: 12560191. doi:10.1016/s1473-3099(03)00514-0.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, Ishida M, Hamaguchi S, Aoshima M, Ariyoshi K, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17(3):313–21. PMID: 28126327. doi:10.1016/S1473-3099(17)30049-X.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Benson P, Sneller VP, Butler JC, Thompson RS, Chen RT, Lewis LS, Carlone G, DeStefano F, Holder P, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA. 1999;281(3):243–48. PMID: 9918479. doi:10.1001/jama.281.3.243.
   PubMed Web of Science ®Google Scholar
• Ohshima N, Nagai H, Matsui H, Akashi S, Makino T, Akeda Y, Oishi K. Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease. Vaccine. 2014;32(10):1181–86. PMID: 24120483. doi:10.1016/j.vaccine.2013.09.060.
   PubMed Web of Science ®Google Scholar
• Musher DM, Manoff SB, McFetridge RD, Liss CL, Marchese RD, Raab J, Rueda AM, Walker ML, Hoover PA. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin. 2011;7(9):919–28. PMID: 21860256. doi:10.4161/hv.7.9.15996.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Bulkow LR, Singleton RJ, Nuorti JP, Hummel KB, Miernyk KM, Zanis C, Whaley M, Romero-Steiner S, Butler JC, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55–74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine. 2011;29(12):2287–95. PMID: 21255685. doi:10.1016/j.vaccine.2011.01.029.
   PubMed Web of Science ®Google Scholar
• Saito W, Nagai H, Suzuki J, Masuda K, Tamura A, Nagayama N, Akagawa S, Kawabe Y, Machida K, Kurashima A, et al. Capsular polysaccharide antibodies after pneumococcal polysaccharide vaccination in patients with chronic respiratory disease. Nihon Kokyuki Gakkai Zasshi. 2005;43(5):277–82. (in Japanese). PMID: 15969208.
   PubMedGoogle Scholar
• Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2001;8(2):266–72. PMID: 11238206. doi:10.1128/CDLI.8.2.266-272.2001.
   PubMedGoogle Scholar
• Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, Benjamin W, Quataert SA, Hildreth S, Sikkema DJ, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003;10(4):514–19. PMID: 12853378. doi:10.1128/cdli.10.4.514-519.2003.
   PubMedGoogle Scholar
• Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol. 2006;13(9):1004–09. PMID: 16960111. doi:10.1128/CVI.00112-06.
   PubMed Web of Science ®Google Scholar
• Chen M, Ssali F, Mulungi M, Awio P, Yoshimine H, Kuroki R, Furumoto A, Tanimura S, Kityo C, Nagatake T, et al. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults. Vaccine. 2008;26(38):4962–68. PMID: 18639599. doi:10.1016/j.vaccine.2008.06.093.
   PubMed Web of Science ®Google Scholar
• Oishi K, Yoshimine H, Watanabe H, Watanabe K, Tanimura S, Kawakami K, Iwagaki A, Nagai H, Goto H, Kudoh S, et al. Drug-resistant genes and serotypes of pneumococcal strains of community-acquired pneumonia among adults in Japan. Respirology. 2006;11(4):429–36. PMID:16771912. doi:10.1111/j.1440-1843.2006.00867.x.
   PubMed Web of Science ®Google Scholar
• Defrance T, Taillardet M, Genestier L. T cell-independent B cell memory. Curr Opin Immunol. 2011;23(3):330–36. PMID: 21482090. doi:10.1016/j.coi.2011.03.004.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Nelson JC, Whitney CG, Neuzil KM, Benson P, Malais D, Baggs J, Mullooly J, Black S, Shay DK. Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the vaccine safety datalink population. Vaccine. 2006;24(2):151–56. PMID: 16122845. doi:10.1016/j.vaccine.2005.07.066.
   PubMed Web of Science ®Google Scholar
• Törling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine. 2003;22(1):96–103. PMID: 14604576. doi:10.1016/s0264-410x(03)00521-8.
   PubMed Web of Science ®Google Scholar